PMID- 10599997
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20201219
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 60
IP  - 11
DP  - 1999 Nov
TI  - Immunization with the HBV core 18-27 epitope elicits CTL responses in humans 
      expressing different HLA-A2 supertype molecules.
PG  - 1013-7
AB  - The human leukocyte antigen (HLA)-A2 restricted HBV core 18-27 epitope is 
      immunodominant in the context of HLA-A2.1 and subdominant in the context of the 
      other HLA-A2 supertype molecules, as defined by frequency of recognition by 
      memory cytotoxic T lymphocyte (CTL) responses from acute hepatitis B virus (HBV) 
      patients, and on the basis of its binding affinity to purified HLA molecules in 
      vitro. Herein, we show that immunization with a lipopeptide containing HBV core 
      18-27 epitope induces CTL responses in patients expressing different HLA-A2 
      supertype molecules, with indistinguishable frequency and magnitude. No 
      difference in responses was noted between patients expressing either one or two 
      different HLA-A2 supertype molecules. Thus, complexes of HBV core 18-27 bound to 
      different HLA-A2 supertype alleles do not appear to act as altered peptide 
      ligands, and do not cross antagonize CTL responses. These results substantiate 
      the immunological relevance of the HLA supertypes concept, and illustrate its 
      potential usefulness for the development of vaccines.
FAU - Livingston, B D
AU  - Livingston BD
AD  - Epimmune, Inc., San Diego, California 92121, USA. blivingston@epimmune.com
FAU - Crimi, C
AU  - Crimi C
FAU - Fikes, J
AU  - Fikes J
FAU - Chesnut, R W
AU  - Chesnut RW
FAU - Sidney, J
AU  - Sidney J
FAU - Sette, A
AU  - Sette A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Hepatitis B Core Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Lipopeptides)
RN  - 0 (Lipoproteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Theradigm-HBV)
SB  - IM
MH  - Acute Disease
MH  - Alleles
MH  - Amino Acid Sequence
MH  - *HLA-A2 Antigen/classification/genetics/metabolism
MH  - Hepatitis B/genetics/*immunology/therapy
MH  - *Hepatitis B Core Antigens/genetics/metabolism
MH  - Hepatitis B Vaccines/pharmacology
MH  - Hepatitis B virus/genetics/*immunology
MH  - Humans
MH  - Immunization
MH  - Immunodominant Epitopes/genetics/metabolism
MH  - Immunologic Memory
MH  - In Vitro Techniques
MH  - Lipopeptides
MH  - Lipoproteins/pharmacology
MH  - Peptide Fragments/pharmacology
MH  - Protein Binding
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 1999/12/22 00:00
MHDA- 1999/12/22 00:01
CRDT- 1999/12/22 00:00
PHST- 1999/12/22 00:00 [pubmed]
PHST- 1999/12/22 00:01 [medline]
PHST- 1999/12/22 00:00 [entrez]
AID - S0198-8859(99)00103-2 [pii]
AID - 10.1016/s0198-8859(99)00103-2 [doi]
PST - ppublish
SO  - Hum Immunol. 1999 Nov;60(11):1013-7. doi: 10.1016/s0198-8859(99)00103-2.